Search Result

Results for "

hepatitis B virus

" in MCE Product Catalog:

By Targets:	HBV (60) HCV (26) Influenza Virus (1) Apoptosis (2) Autophagy (1) DNA/RNA Synthesis (5) Drug Metabolite (1) Endogenous Metabolite (1) Ferroptosis (1) Fungal (1) GABA Receptor (1) Glucosidase (1) HCV Protease (8) HIV (6) Integrin (1) NADPH Oxidase (1) Nucleoside Antimetabolite/Analog (2) Reverse Transcriptase (3) RSV (1) SARS-CoV (9) Toll-like Receptor (TLR) (1) Transthyretin (TTR) (1)
By Research Areas:	Cancer (5) Infection (90) Inflammation/Immunology (11) Metabolic Disease (1) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: HCV HBV Influenza Virus Virus Protease

Cat. No.	Product Name	Target	Research Areas

HY-P4042

Hepatitis B Virus Receptor Binding Fragment hepatitis B peptide 4980	HBV	Infection Inflammation/Immunology
Hepatitis B Virus Receptor Binding Fragment (hepatitis B peptide 4980) is a synthetic peptide analog which specifically binds to Hep G2 cells. Hepatitis B Virus Receptor Binding Fragment is a promising immunogen expected to elicit protective antibodies based on the concept of the attachment blockade pathway of virus neutralization.

HY-P1774

Hepatitis B Virus Core (128-140)
HBV Infection

Hepatitis B Virus Core (128-140) is a peptide of hepatitis B virus core protein.

Hepatitis B Virus Core (128-140)	HBV	Infection
Hepatitis B Virus Core (128-140) is a peptide of hepatitis B virus core protein.

HY-P4043

Hepatitis b virus pre-s region (120-145)	HBV	Infection Inflammation/Immunology
Hepatitis b virus pre-s region (120-145) is a preS2 peptide that inhibits the binding of single-chain Fv fragment (scFv) or IgG to r-HBsAg.

HY-P4038

Hepatitis C Virus S5A/5B	HCV Protease	Infection
Hepatitis C Virus S5A/5B is a synthetic peptide substrate. Hepatitis C Virus S5A/5B mimics the NS5A/5B junction of the nonstructural protein (NS), served as the substrate for the study of HCV NS3 protease activity.

HY-121513

Torcitabine 2'-Deoxy-L-cytidine; L-dC	HBV	Infection
Torcitabine (2'-Deoxy-L-cytidine) is an antiviral agent. Torcitabine has the potential for chronic hepatitis B virus infection treatment.

HY-N0639

Punicalin	HBV	Infection Inflammation/Immunology
Punicalin is a hydrolyzable tannin isolated from Punica granatum L. or the leaves of Terminalia catappa L.. Punicalin is a anti-hepatitis *B virus* (HBV)** agent and has anti-inflammatory activity.

HY-P4045

HBV Seq2 aa:208-216
HBV Infection

HBV Seq2 aa:208-216, a HBsAg derived CD8 epitope peptide, is studied as part of Large envelope protein from Hepatitis B virus.
HY-P4051

HBV Seq1 aa:141-151
HBV Infection Inflammation/Immunology

HBV Seq1 aa:141-151 is a peptide. HBV Seq1 aa:141-151 can be used for the research of chronic hepatitis B virus (HBV) .

HBV Seq2 aa:208-216	HBV	Infection
HBV Seq2 aa:208-216, a HBsAg derived CD8 epitope peptide, is studied as part of Large envelope protein from Hepatitis B virus.

HBV Seq1 aa:141-151	HBV	Infection Inflammation/Immunology
HBV Seq1 aa:141-151 is a peptide. HBV Seq1 aa:141-151 can be used for the research of chronic hepatitis B virus (HBV) .

HY-114314

BA-53038B	HBV	Infection
BA-53038B is a HBV core protein allosteric modulator (CpAM), binding to the HAP pocket and modulating HBV capsid assembly. BA-53038B has antiviral activity for hepatitis B virus (HBV) with an EC₅₀ value of 3.32 μM. BA-53038B can be used for the research of chronic hepatitis B.

HY-Y0073

4-Hydroxyacetophenone P-hydroxyacetophenone	HBV	Infection Inflammation/Immunology
4-Hydroxyacetophenone (P-hydroxyacetophenone) is a key hepatoprotective and choleretic compound in Artemisia capillaris and A. morrisonensis, also has an anti-hepatitis B virus effect and anti-inflammatory effect.

HY-145713

HBV-IN-19	HBV	Infection
HBV-IN-19 inhibits hepatitis B virus (HBV) infection. Inhibiting HBsAg secretion and/or production is a strategy for the treatment of HBV infection, including chronic HBV infection.

HY-W352344

2'-Deoxy-L-adenosine	HBV	Infection
2'-Deoxy-L-adenosine is an orally active synthon for modified oligodeoxyribonucleotides. 2'-Deoxy-L-adenosine is a potent, specific and selective inhibitor of the replication of hepatitis B virus (HBV) as well as the closely related duck and woodchuck hepatitis viruses (WHV).

HY-145713A

HBV-IN-19 TFA	HBV	Infection
HBV-IN-19 TFA inhibits hepatitis B virus (HBV) infection. Inhibiting HBsAg secretion and/or production is a strategy for the treatment of HBV infection, including chronic HBV infection.

HY-134790

GST-HG131	HBV	Infection
GST-HG131 is a specific inbihitor of hepatitis B virus (HBV) surface antigen, belongs to dihydrobenzopyridooxazepine (DBP) series. GST-HG131 exhibits excellent and specific HBV antigens inhibition with EC₅₀ of 28.2 nM (HBsAg) and 16.0 nM (HBeAg), respectively, but also it is safety for animal.

HY-126033

Sophoranol	HBV RSV	Infection
Sophoranol is an alkaloid that can be isolated from S. flavescens, with antiviral activity. Sophoranol has anti-HBV (hepatitis B virus) activity. Sophoranol shows potent antiviral activities against *respiratory syncytial virus* (RSV) with an IC₅₀** of 10.4 μg/mL.

HY-148201

Oleana-2,12-dien-28-oic acid	HBV	Infection
Oleana-2,12-dien-28-oic acid is an HBV-DNA inhibitor, HBsAg and HBeAg inhibitor. Oleana-2,12-dien-28-oic acid can be used in hepatitis B virus infection disease research.

HY-P4046

HBV Seq2 aa:179-186	HIV	Inflammation/Immunology
HBV Seq2 aa:179-186 serve as effective motifs for CTL response in H-2b system after in vitro restimulation of the primed T cells. HBV Seq2 aa:179-186 is a novel epitope identified on the surface antigen of hepatitis B virus.

HY-133721

Chamaechromone	HBV	Infection Inflammation/Immunology
Chamaechromone is a biflavonoid ingredient isolated from the roots of Stellera chamaejasme L. (Thymelaeaceae). Chamaechromone possesses *anti-hepatitis* B virus (HBV)** effects against the surface antigen of HBV (HBsAg) secretion and has insecticidal activities.

HY-126970

HBF-0259	HBV	Infection
HBF-0259 is a potent and selective inhibitor of hepatitis B virus (HBV) surface antigen (HBsAg) secretion, with an EC₅₀ of 1.5 μM in HepG2.2.15 cells. HBF-0259 has no effect on HBV DNA synthesis.

HY-19447

Besifovir LB80331	HBV	Infection
Besifovir (LB80331), a parent agent converted by LB80380 (HY-19447A), further metabolizes to its active form, LB80317 (HY-106235). Besifovir is an orally active, novel antiviral agent against hepatitis B virus (HBV).

HY-119691

Alamifovir LY582563; MCC-478	HBV	Infection
Alamifovir (LY582563; MCC-478), a purine nucleotide analogue proagent, shows potent activity against wild type and lamivudine resistant hepatitis B virus (HBV). Alamifovir has high activity against HBV replication and sustained antiviral effect.

HY-116999

IR415	HBV	Infection
IR415 is a potent anti-HBV agent and inhibits HBV replication by blocking the HBx activity. IR415 selectively interacts with HBx (K_d=2 nM) and blocks HBV-mediated RNAi suppression, reverses the inhibitory effect of HBx protein on the activity of the dicer endoribonuclease. HBx: hepatitis B virus X protein.

HY-109168

Bersacapavir
JNJ-6379; JNJ-56136379
HBV Infection

Bersacapavir is a novel Hepatitis B Virus capsid assembly modulator.
HY-103487

Uprifosbuvir
IDX21437; MK-3682
HCV Infection

Uprifosbuvir is an antiviral agent. Uprifosbuvir is a NS5b inhibitor developed for the research of chronic hepatitis C virus.
HY-P99693

Lenvervimab
GC1102
HBV Infection

Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection.
HY-112564

JNJ-632
HBV Infection

JNJ-632 is a hepatitis B virus (HBV) capsid assembly modulator (CAM).
HY-N3861

Erythrocentaurin
HBV Infection

Erythrocentaurin, a natural compound, is a new class of hepatitis B virus inhibitor.
HY-N10543

5-O-(E)-p-Coumaroylquinic acid
HBV Infection

5-O-(E)-p-Coumaroylquinic acid, a quinic acid derivative, is a potent phytochemical agent against hepatitis B virus.
HY-14775

Nesbuvir
HCV-796
HCV Infection

Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase.
HY-106233

Tiviciclovir
AM188
HBV Infection

Tiviciclovir (AM188) is an antiviral guanosine analog and a hepatitis B virus inhibitor.
HY-100029

Bay 41-4109
HBV Infection

BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC₅₀ of 53 nM.
HY-P4049

HBV Seq1 aa:63-71
HBV Infection

HBV Seq1 aa:63-71 is the fragment of hepatitis B virus (HBV).
HY-12634

Deleobuvir
BI 207127
HCV Infection

Deleobuvir (BI 207127) is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor.

Bersacapavir JNJ-6379; JNJ-56136379	HBV	Infection
Bersacapavir is a novel **Hepatitis B Virus** capsid assembly modulator.

Uprifosbuvir IDX21437; MK-3682	HCV	Infection
Uprifosbuvir is an antiviral agent. Uprifosbuvir is a NS5b inhibitor developed for the research of chronic hepatitis C virus.

Lenvervimab GC1102	HBV	Infection
Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection.

JNJ-632	HBV	Infection
JNJ-632 is a hepatitis B virus (HBV) capsid assembly modulator (CAM).

Erythrocentaurin	HBV	Infection
Erythrocentaurin, a natural compound, is a new class of hepatitis B virus inhibitor.

5-O-(E)-p-Coumaroylquinic acid	HBV	Infection
5-O-(E)-p-Coumaroylquinic acid, a quinic acid derivative, is a potent phytochemical agent against **hepatitis B virus**.

Nesbuvir HCV-796	HCV	Infection
Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase.

Tiviciclovir AM188	HBV	Infection
Tiviciclovir (AM188) is an antiviral guanosine analog and a hepatitis B virus inhibitor.

Bay 41-4109	HBV	Infection
BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC₅₀ of 53 nM.

HBV Seq1 aa:63-71	HBV	Infection
HBV Seq1 aa:63-71 is the fragment of hepatitis B virus (HBV).

Deleobuvir BI 207127	HCV	Infection
Deleobuvir (BI 207127) is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor.

HY-19447A

Besifovir Dipivoxil maleate LB80380 maleate	HBV	Infection
Besifovir Dipivoxil maleate (LB80380 maleate) is an oral proagent of LB80317. Besifovir Dipivoxil maleate (LB80380 maleate) is effective in hepatitis B virus (HBV) DNA suppression for both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients in preliminary studies^[2]

HY-B0017

Telbivudine Epavudine; L-Thymidine; NV 02B	HBV	Infection
Telbivudine (Epavudine), an orally active thymidine nucleoside analog, is a potent antiviral inhibitor of hepatitis B virus (HBV) replication.

HY-100029A

Bay 41-4109 racemate
HBV Infection

BAY 41-4109 racemate is the racemate of BAY 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC₅₀ of 53 nM.
HY-P4050

HBV Seq1 aa:18-27
HBV Infection

HBV Seq1 aa:18-27 is a hepatitis B virus (HBV) core antigen 18-27 peptide fragment.
HY-P4048

HBV Seq1 aa:93-100
HBV Infection

HBV Seq1 aa:93-100 is a hepatitis B virus (HBV) core antigen 93-100 peptide fragment.

Bay 41-4109 racemate	HBV	Infection
BAY 41-4109 racemate is the racemate of BAY 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC₅₀ of 53 nM.

HBV Seq1 aa:18-27	HBV	Infection
HBV Seq1 aa:18-27 is a hepatitis B virus (HBV) core antigen 18-27 peptide fragment.

HBV Seq1 aa:93-100	HBV	Infection
HBV Seq1 aa:93-100 is a hepatitis B virus (HBV) core antigen 93-100 peptide fragment.

HY-W012738

DL-Pyroglutamic acid	Influenza Virus GABA Receptor	Infection
DL-Pyroglutamic acid (CAE) as an inactivator of hepatitis B surface, inactivates vaccinia virus, herpes simplex virus, and influenza virus except poliovirus. DL-Pyroglutamic acid is also a possible inhibitor of GABA transaminase, increases GABA amount with antiepileptic action.

HY-124600

NVR 3-778	HBV	Infection
NVR 3-778 is a first-in-Class and oral bioavailable HBV CAM (capsid assembly modulator) belonging to the SBA (sulfamoylbenzamide) class, with anti-HBV activity.

HY-111003

Isothiafludine NZ-4	HBV	Infection
Isothiafludine is an orally active non-nucleosidic anti-HBV compound. Isothiafludine inhibits hepatitis B virus replication by blocking pregenomic RNA encapsidation.

HY-109137

Selgantolimod GS-9688	Toll-like Receptor (TLR) HBV	Infection
Selgantolimod (GS-9688) is an orally active, potent and selective toll-like receptor 8 (TLR8) agonist for the treatment of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection.

HY-136266

HCV-IN-29
HCV Cancer

HCV-IN-29 is a hepatitis C virus (HCV) inhibitor exacted from patent US8329159B2, compound 1e.

HCV-IN-29	HCV	Cancer
HCV-IN-29 is a hepatitis C virus (HCV) inhibitor exacted from patent US8329159B2, compound 1e.

HY-14844

Lagociclovir MIV-210	HBV	Infection
Lagociclovir (FLG) is a nucleoside analogue that inhibits wild-type hepatitis B virus (HBV) replication in a human hepatoma cell line permanently expressing HBV.

HY-I0719

Sofosbuvir impurity B	Drug Metabolite	Others
Sofosbuvir impurity B is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

HY-15602B

Ledipasvir D-tartrate GS-5885 D-tartrate	HCV	Infection
Ledipasvir D-tartrate is an inhibitor of the hepatitis C virus NS5A, with EC₅₀ values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-148560

ccc_R08	HBV DNA/RNA Synthesis	Infection
ccc_R08 is a non-cytotoxic and orally active cccDNA inhibitor that reduces cccDNA levels in the liver of HBV-infected mice. ccc_R08 can be used in the study of HBV virus (hepatitis B virus) infection.

HY-100029B

Bay 41-4109 (less active enantiomer)	HBV	Infection
Bay 41-4109 less active enantiomer shows less activity than Bay 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC₅₀ of 53 nM.

HY-B0017S

Telbivudine-d4 Epavudine-d₄; L-Thymidine-d₄; NV 02B-d₄	HBV	Infection
Telbivudine-d₄ is deuterium labeled Telbivudine. Telbivudine (Epavudine), an orally active thymidine nucleoside analog, is a potent antiviral inhibitor of hepatitis B virus (HBV) replication[1].

HY-148171

L-2'-Fd4C	HIV HBV DNA/RNA Synthesis Nucleoside Antimetabolite/Analog	Infection
L-2'-Fd4C, is an l-nucleoside analogue. L-2'-Fd4C has anti-*human immunodeficiency virus* (HIV) and anti-hepatitis B virus (HBV)** activity.

HY-147255A

(S)-Canocapavir (S)-ZM-H1505R	Others	Infection
(S)-Canocapavir is the isomer of Canocapavir (HY-147255A). Canocapavir (ZM-H1505R) has orally antiviral activity. Canocapavir is a HBV capsid inhibitor that can be used in the research of Chronic hepatitis B.

HY-147255

Canocapavir ZM-H1505R	HBV	Infection
Canocapavir (ZM-H1505R) has orally antiviral activity. Canocapavir is a HBV capsid inhibitor that can be used in the research of Chronic hepatitis B. .

HY-12429

Beclabuvir BMS-791325	HCV	Infection
Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC₅₀ of < 28 nM.

HY-135330

Lamivudine 13C,15N2	HIV Reverse Transcriptase	Infection
Lamivudine 13C,15N2 is a labelled impurity of Lamivudine (BCH-189). Lamivudine is a nucleoside reverse transcriptase inhibitors (NRTIs), and can inhibit HIV reverse transcriptase 1/2 and the reverse transcriptase of hepatitis B virus.

HY-123767

HEC72702	HBV	Infection
HEC72702 is a potent and orally active hepatitis B virus capsid inhibitor with an EC₅₀ values of 0.039 µM. HEC72702 dose-dependently reduced HBV DNA in both the plasma and livers.

HY-15789

Elbasvir MK-8742	HCV	Infection
Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) inhibitor with EC₅₀s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.

HY-147763

HCV-IN-39	HCV	Infection
HCV-IN-39 (Compound 18a) is a potent hepatitis C virus (HCV) nucleoside inhibitor with EC₅₀ values of 0.644, 0.952 and 0.154 μM against GT1a, GT1b and GT1b CES1 replicons.

HY-N0854

Alisol F	HBV	Infection
Alisol F is a triterpene isolated from Alisma orinentale, has immunosuppressive and anti-virus functions. Alisol F exhibits inhibitory activity in vitro on hepatitis B virus (HBV) surface antigen (HBsAg) secretion of the HepG2.2.15 cell line with an IC₅₀ of 0.6 μM.

HY-P99497

Cepeginterferon alfa-2b	Integrin HCV	Infection
Cepeginterferon alfa-2b is a pegylated interferon. And Cepeginterferon alfa-2b has PEG with molecular weight of 20 kDa as a pegylated base. Cepeginterferon alfa-2b can be used for research of various diseases, such as hepatitis C virus (HCV), polycythemia vera (PV) and essential thrombocythemia (ET).

HY-10468

NM107 2'-C-Methylcytidine; NM-107	HCV	Infection
NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC₅₀ of NM107 in the wild-type replicon cells is 1.85 μM.

HY-N6939

Pseudolaric Acid B	HBV Fungal Apoptosis Autophagy Ferroptosis	Cancer Infection Inflammation/Immunology
Pseudolaric Acid B is a diterpene isolated from the root of Pseudolarix kaempferi (pinaceae), has anti-cancer, antifungal, and antifertile activities, and shows immunosuppressive activity on T lymphocytes. Pseudolaric Acid B inhibits hepatitis B virus (HBV) secretion through apoptosis and cell cycle arrest. Pseudolaric Acid B induces autophagy.

HY-148560B

cis-ccc_R08	HBV	Infection
cis-ccc_R08 (compound 1) is a flavonoid derivative that can be used in the study of **hepatitis B virus (HBV**) infection. cis-ccc_R08 is a cccDNA (covalently closed circular DNA) inhibitor.

HY-P4044

HBV Seq2 aa:28-39
HBV Infection

HBV Seq2 aa:28-39 is a HBsAg peptide, which binds to major histocompatibility complex (MHC) class I molecules.

HY-148172

L-Fd4A	HIV HBV Nucleoside Antimetabolite/Analog	Infection
L-Fd4A is an adenine derivative. L-Fd4A has anti-*human immunodeficiency virus* (HIV) (EC₅₀=1.5 μM) and anti-hepatitis B virus (HBV) (EC₅₀**=1.7 μM) activity. L-Fd4A has low cytotoxicity.

HY-147764

HCV-IN-40	HCV	Infection
HCV-IN-40 (Compound 18c) is a potent, orally active hepatitis C virus (HCV) nucleoside inhibitor with EC₅₀ values of 0.259, 0.434 and 0.069 μM against GT1a, GT1b and GT1b CES1 replicons.

HY-148560A

trans-ccc_R08	HBV	Infection
trans-ccc_R08 (compound 1-B) is a potent cccDNA (covalently closed circular DMA) inhibitor. trans-ccc_R08 inhibits HBeAg level with an IC₅₀ value of 0.08 µM. trans-ccc_R08 has the potential for the research of Hepatitis B Virus infection (HBV).

HY-B0250

Lamivudine BCH-189	HIV Reverse Transcriptase HBV	Infection Cancer
Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of **hepatitis B virus**. Lamivudine salicylate can penetrate the CNS.

HY-112047

GSK8175 GSK2878175	HCV	Infection
GSK8175 is a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV). GSK8175 is a sulfonamide- N-benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons.

HY-101954

Inarigivir ORI-9020; SB-9000	HBV	Infection
Inarigivir (ORI-9020) is a dinucleotide antiviral drug that can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) act as a RIG-I agonist to activate cellular innate immune responses.

HY-B0250A

Lamivudine salicylate BCH-189 salicylate	HIV Reverse Transcriptase HBV	Infection
Lamivudine (BCH-189) salicylate is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine salicylate can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of **hepatitis B virus**. Lamivudine salicylate can penetrate the CNS.

HY-145052

HBV-IN-9	HBV	Infection
HBV-IN-9 is a potent HBsAg (HBV Surface antigen) inhibitor (IC₅₀=10 nM) and HBV DNA production inhibitor (IC₅₀=0.15 nM in HepG2.2.15 cells). From patent WO2018001952A1, example 20.

HY-13998A

Dasabuvir sodium ABT-333 sodium	HCV DNA/RNA Synthesis	Infection
Dasabuvir (ABT-333) sodium is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir sodium inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir sodium inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively.

HY-13998

Dasabuvir ABT-333	HCV DNA/RNA Synthesis	Infection
Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively.

HY-15591A

TMC647055 Choline salt	HCV	Infection
TMC647055 (Choline salt) is a potent nonnucleoside NS5B polymerase inhibitor of HCV replication. TMC647055 Choline salt has potent HCV combine activity with an IC₅₀ value of 82 nM. TMC647055 Choline salt can be used for the research of Hepatitis C virus (HCV).

HY-15602C

Ledipasvir hydrochloride GS-5885 hydrochloride	HCV SARS-CoV	Infection
Ledipasvir (GS-5885) hydrochloride is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir hydrochloride is also a SARS-CoV 3CL^pro inhibitor with an IC₅₀ of 1.62 μM.

HY-15602

Ledipasvir GS-5885	HCV SARS-CoV	Infection
Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL^pro inhibitor with an IC₅₀ of 1.62 μM.

HY-19921

JTK-853	HCV	Infection
JTK-853 is a novel, non-nucleoside **Hepatitis C Virus (HCV) polymerase inhibitor which shows effective antiviral activity in HCV replicon cells with EC₅₀**s of 0.38 and 0.035 µM in genotype 1a H77 and 1b Con1 strains, respectively.

HY-N3239

Mulberrofuran G	NADPH Oxidase HBV
Mulberrofuran G protects ischemic injury-induced cell death via inhibition of NOX4-mediated ROS generation and ER stress. Mulberrofuran G shows moderate inhibiting activity of hepatitis B virus (HBV) DNA replication with IC₅₀ of 3.99 μM.

HY-147885

HCV-IN-41	HCV	Infection
HCV-IN-41 (compound 4) is a highly potent hepatitis C virus (HCV) inhibitor with an EC₅₀ value of 0.006762 nM, 5.183 nM, 1.365 nM and 142.2 nM for HCV genotype 1b, 2a, 3a and 4a, respectively. HCV-IN-41 reduces HCV RNA replication.

HY-109195

Vebicorvir ABI-H0731	HBV	Infection Inflammation/Immunology
Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC₅₀s from 1.84 μM to 7.3 μM.

HY-101954A

Inarigivir ammonium ORI-9020 ammonium; SB-9000 ammonium	HBV	Infection Inflammation/Immunology
Inarigivir (ORI-9020) ammonium is a dinucleotide antiviral drug that can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) ammonium acts as a RIG-I (Retinoic acid-inducible gene-I) agonist to activate cellular innate immune responses.

HY-15602S

Ledipasvir-d6 GS-5885-d₆	HCV SARS-CoV	Infection
Ledipasvir-d₆ is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM[3].

HY-100028

AT-130	HBV DNA/RNA Synthesis	Cancer Infection
AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC₅₀ of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells.

HY-N0063

Punicalagin	SARS-CoV HBV	Cancer Infection Metabolic Disease
Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive 3CL^pro inhibitor and inhibits SARS-CoV-2 replication in vitro. Punicalagin is an *anti-hepatitis* B virus (HBV)** agent and has antioxidant, anti-inflammatory, and anticancer effects. Punicalagin has the potential for the research of COVID-19.

HY-146126

NS5A-IN-4	HCV Protease	Infection
NS5A-IN-4 (Compound 1.12) is an orally active pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with IC₅₀ values of 1.2, 2296, 4.6, 362, 10.3 and 693 pM against *gT1b, gT1a, gT2a, gT3a, gT4a* and gT5a.

HY-15298C

Grazoprevir sodium salt MK-5172 sodium salt	HCV HCV Protease SARS-CoV	Infection
Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively. Grazoprevir sodium salt inhibits SARS-CoV-2 3CL^pro activity.

HY-15298B

Grazoprevir hydrate MK-5172 hydrate	HCV HCV Protease SARS-CoV	Infection
Grazoprevir hydrate (MK-5172 hydrate) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively. Grazoprevir hydrate inhibits SARS-CoV-2 3CL^pro activity.

HY-15298

Grazoprevir MK-5172	HCV Protease HCV SARS-CoV	Infection
Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively. Grazoprevir inhibits SARS-CoV-2 3CL^pro activity.

HY-15298A

Grazoprevir potassium salt MK-5172 potassium salt	HCV HCV Protease SARS-CoV	Infection
Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with K_is of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively. Grazoprevir potassium salt inhibits SARS-CoV-2 3CL^pro activity.

HY-125371

2'-C-Methyladenosine	HCV	Infection Inflammation/Immunology
2'-C-Methyladenosine is an inhibitor of hepatitis C virus (HCV) replication. 2'-C-Methyladenosine inhibits HCV replicon and NS5B-catalyzed RNA synthesis with IC₅₀ values of 0.3μM and 1.9 μM, respectively. 2'-C-Methyladenosine also potently inhibits LRV1 in Leishmania guyanensis (Lgy) and Leishmania braziliensis.

HY-15256

Faldaprevir BI 201335	HCV Protease	Infection
Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with K_i values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC₅₀ values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection.

HY-151134

HBV-IN-25	HBV	Infection
HBV-IN-25 is a good potency, orally active novel HBV cccDNA reducer. HBV-IN-25 has anti-HBeAg potency and anti-HBV activity with IC₅₀ values of 0.58 μM and 1.15 μM, respectively. HBV-IN-25 has good aqueous solubility (LYSA＞452 μg/mL) and good PK property with no cellular toxicity.

HY-N0058

4,5-Dicaffeoylquinic acid Isochlorogenic acid C	HBV Endogenous Metabolite Apoptosis Glucosidase	Infection
4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects.

HY-10238

Danoprevir ITMN-191; R7227; RO5190591; RG7227	HCV Protease HCV SARS-CoV	Infection
Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC₅₀ of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC₅₀ higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC₅₀s=0.2-0.4 nM) as well as 2b and 3a (IC₅₀s=1.6, 3.5 nM). Danoprevir is also a SARS-CoV 3CL^pro inhibitor with an IC₅₀ of 0.05 μM.

HY-148089

Eplontersen	Transthyretin (TTR)	Neurological Disease
Eplontersen is a triantennary N-acetyl galactosamine (GalNAc₃-7a)-conjugated antisense oligonucleotide targeting transthyretin (TTR) mRNA to inhibit production of both variant and wild-type TTR protein. Misfolded TTR induces amyloid fibrils formation in the heart and peripheral nerves, leads to amyloid TTR (ATTR) amyloidosis diseases.

Cat. No.	Product Name

HY-L113

Antiviral Traditional Chinese Medicine Active Compound Library

166 compounds

Increasing research have shown that Traditional Chinese Medicine (TCM) possess antiviral activities against various viral strains, such as herpes simplex virus, influenza virus, hepatitis B and C viruses, and SARS-CoV. To date, dozens of Chinese herbs and hundreds of natural TCM ingredients have been reported to exhibit good antiviral activities. Active components from TCM are one of the important sources for antiviral drugs discovery.

MCE designs a unique collection of 166 active compounds of antiviral Chinese Herbal Medicines. MCE Antiviral Traditional Chinese Medicine Active Compound Library is a useful tool for discovery antiviral drugs from TCM.

Cat. No.	Product Name	Target	Research Area